Research Paper Volume 16, Issue 4 pp 3160—3184
Single-cell and bulk RNA sequencing data jointly reveals VDAC2’s impacts on prognosis and immune landscape of NSCLC
Figure 5. Hypoxia heterogeneous NSCLC subpopulation related VDAC2 showed important prognostic value and tumor promoting role in NSCLC. (A) The expression of VDAC2 in normal and cancer samples basing on TCGA-LUAD cohort. (B) The expression of VDAC2 in NSCLC tissues and normal tissues basing on Human protein atlas database. (C) The expression of VDAC2 in different stages of NSCLC patients. (D, E) The levels of VDAC2 mRNA and protein in clinical NSCLC tissues. (F) The expression of VDAC2 in lung cancer and adjacent noncancerous tissues was detected by immunofluorescence. (G, H) The levels of VDAC2 mRNA and protein expression in A549 and NCI-H1299 cells. * p<0.05, ** p<0.01, **** p<0.0001.